VentriPoint Diagnostics ("VentriPoint") (TSX VENTURE:VPT), a company focused on
providing effective 3D technology to monitor right heart function in children
and adults, today announced the second successful deployment of its VentriPoint
Medical System ("VMS") at the Rikshospitalet University Hospital in Oslo,
Norway.


"This deployment of our tool in Europe is a milestone for VentriPoint and we are
delighted that Dr. Henrik Brun and his colleagues will be using the system on
Tetralogy of Fallot (a heart disease usually referred to as 'blue-baby')
patients as well as expanding the use to patients who have had a valve implanted
in their pulmonary artery," said Dr. George Adams, VentriPoint's CEO.


"We are enthusiastic to begin to use the VentriPoint system with patients in our
hospital. The ease of use of the system and its potential to replace MRI studies
will hopefully make a difference in the care of children with congenital heart
disease," said Dr. Henrik Brun, cardiologist at Rikshospitalet.


The Rikshospitalet University Hospital is a national reference hospital
responsible for introducing and developing new medical examination methods,
treatment methods and follow-ups. It conducts more than 50 per cent of the total
medical research in Norwegian medical centres. 


What is significant about this deployment is that it is the second installation
of the diagnostic tool of the ten slated for advancing the merit and value of
the VentriPoint system in diagnosing heart disease in children and adults. The
company is manufacturing ten systems and has selected seven leading pediatric
cardiologists at world-renown hospitals to be the first users. The last three
systems will be going to adult cardiologists with large patient groups with
pulmonary hypertension. A number of European, Canadian and US hospitals have
submitted a request to be one of the first adult users. The company will decide
by the end of the year the last three sites for this deployment. Additional
systems will become available next year as the company obtains reimbursement
codes and expands the applications to a broader array of congenital heart
diseases and pulmonary hypertension.


There are 191 specialized pediatric hospitals in Europe, which would benefit
from VMS systems, which diagnoses and monitors children with congenital heart
disease (CHD). In addition, there are many hospitals, which monitor adults with
CHD. The company estimates the European market for its system for CHD would be
$20M per year and more than $100M for other heart disorders.


In other news, VentriPoint will today file its quarterly financial statements
and MD&A and they can be viewed on www.sedar.com.


About VentriPoint Diagnostics Ltd.: VentriPoint has created a diagnostic
ultrasound tool to monitor patients with heart disease, a leading cause of death
in developed countries. VMS is the first cost-effective and accurate diagnostic
tool for measuring right ventricle heart function. Congenital heart disease in
children is the first application in a suite of applications for all major heart
diseases including pulmonary hypertension, cardiovascular disease and heart
failure - a multibillion dollar market potential. Canada and Europe (CE Mark)
have granted approval for the sale of its VMS diagnostic tool and a 510(k)
submission is currently being reviewed by the U.S. Federal Drug Administration.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.